Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | XBP1 | P17861 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.45 |
| ▸ | HTR1E | P28566 | 1/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL387339 | 0.79 | ALDH1A1 (0.54) | ALDH1A1GAAKMT2AMAPTNPSR1 | |
| SCHEMBL3180528 | 0.78 | ADORA2A (0.59) | MAPTSMN1; SMN2GLAHSD17B10CYP2C9 | |
| SCHEMBL10309249 | 0.78 | ALDH1A1 (0.49) | ALDH1A1GAAKMT2AMAPTNPSR1 | |
| SCHEMBL1241218 | 0.78 | ALDH1A1 (0.49) | ALDH1A1GAAKMT2AMAPTNPSR1 | |
| SCHEMBL6890038 | 0.78 | CHRNB2 (0.53) | ALDH1A1GAAKMT2AMAPTNPSR1 | |
| SCHEMBL18343921 | 0.78 | ALDH1A1 (0.49) | ALDH1A1GAAKMT2AMAPTNPSR1 | |
| SCHEMBL3178085 | 0.76 | ADORA2A (0.58) | ALDH1A1GAAKMT2AMAPTATM | |
| SCHEMBL10309259 | 0.75 | ALDH1A1 (0.61) | ALDH1A1GAAKMT2AMAPTNPSR1 | |
| SCHEMBL2473169 | 0.75 | ADORA2A (0.53) | ALDH1A1KMT2AMAPTMAPK1SMN1; SMN2 | |
| SCHEMBL3178135 | 0.75 | MEN1 (0.46) | ALDH1A1KMT2AMAPTMAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-5276989-A | — | — | None | — | — | JP | disclosed |
| JP-10175853-A | — | — | None | — | — | JP | disclosed |
| US-7838529-B2 | Xanthine derivates, their preparation and their use in pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-23 | — | — | US | disclosed |
| US-20090131432-A1 | XANTHINE DERIVATES, THEIR PREPARATION AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-05-21 | — | — | US | disclosed |
| US-7524847-B2 | Fused 1,3-dihydro-imidazole ring compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-04-28 | — | — | US | disclosed |
| US-7495005-B2 | Xanthine derivatives, their preparation and their use in pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-02-24 | — | — | US | disclosed |
| US-7074798-B2 | Xanthine derivative and DPPIV inhibitor | EISAI CO., LTD (JP) | 2006-07-11 | — | — | US | disclosed |
| EP-1338595-B1 | Xanthine derivatives as DPP-IV inhibitors | EISAI CO LTD (JP) | 2006-05-03 | — | — | EP | disclosed |
| EP-1554278-B1 | XANTHINE DERIVATIVES, PRODUCTION THEREOF AND USE THEREOF AS MEDICINES | BOEHRINGER INGELHEIM PHARMA (DE) | 2006-04-12 | — | — | EP | disclosed |
| EP-1554278-A2 | XANTHINE DERIVATIVES, PRODUCTION THEREOF AND USE THEREOF AS MEDICINES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-07-20 | — | — | EP | disclosed |
| EP-1018546-B1 | MICROORGANISMS PRODUCING 5-AMINOLEVULINIC ACID AND PROCESSES FOR PRODUCING 5-AMINOLEVULINIC ACID BY USING THE SAME | COSMO RES INST (JP) | 2005-04-13 | — | — | EP | disclosed |
| US-20040166125-A1 | Xanthine derivatives, their preparation and their use in pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-08-26 | — | — | US | disclosed |
| US-20040082570-A1 | Xanthine derivative and DPPIV inhibitor | EISAI CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| WO-2004018467-A2 | PHENACYL XANTHINE DERIVATIVES AS DPP-IV INHIBITOR | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-04 | — | — | WO | disclosed |
| EP-1338595-A2 | Xanthine derivatives as DPP-IV inhibitors | Eisai Co., Ltd. (JP) | 2003-08-27 | — | — | EP | disclosed |
| US-6342377-B1 | AEROBIC PROCESS | COSMO RESEARCH INTITUTE (JP) | 2002-01-29 | — | — | US | disclosed |
| EP-1018546-A1 | MICROORGANISMS PRODUCING 5-AMINOLEVULINIC ACID AND PROCESSES FOR PRODUCING 5-AMINOLEVULINIC ACID BY USING THE SAME | Cosmo Research Institute (JP) | 2000-07-12 | — | — | EP | disclosed |
| JP-H10175853-A | APOTOSIS INDUCING AGENT | COSMO SOGO KENKYUSHO:KK | 1998-06-30 | — | — | JP | disclosed |
| JP-H05276989-A | PRODUCTION OF CAROTENOIDS AND CAROTENOID COMPOUND | COSMO SOGO KENKYUSHO:KK | 1993-10-26 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082570-A1 | Xanthine derivative and DPPIV inhibitor | DPP4, DPP9, DPP7 | ALDH1A1 112/4885GAA 2197/4885KMT2A 2570/4885 |
| US-20040166125-A1 | Xanthine derivatives, their preparation and their use in pharmaceutical compositions | XDH, CALCRL, CALCA | ALDH1A1 160/4885GAA 1829/4885KMT2A 4610/4885 |
| US-20090131432-A1 | XANTHINE DERIVATES, THEIR PREPARATION AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS | XDH, CALCRL, GPR119 | ALDH1A1 274/4885GAA 1746/4885KMT2A 4285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.